Invitrogen Entering Gene Analysis Market Via Research Genetics
This article was originally published in The Gray Sheet
Executive Summary
Invitrogen's acquisition of Research Genetics in a stock transaction valued at $158 mil. will allow the company's expanded sales force to offer products and services in four key areas of the genomic discovery cycle.
You may also be interested in...
Invitrogen
Research partnership with the Novartis Institute for Functional Genomics is announced Dec. 17. The agreement allows Novartis access to Invitrogen's cloning and expression kits in exchange for commercial rights to any genes discovered by NIFG using the technology (1see related story, p. 19)
Invitrogen
Research partnership with the Novartis Institute for Functional Genomics is announced Dec. 17. The agreement allows Novartis access to Invitrogen's cloning and expression kits in exchange for commercial rights to any genes discovered by NIFG using the technology (1see related story, p. 19)
Invitrogen/Novex
Definitive stock-swap merger agreement valued at over $50 mil. would combine San Diego-based Novex, a supplier of pre-cast electrophoresis gels and related instruments, with Invitrogen, maker of research tool kits for gene cloning and protein expression, also based in San Diego. Combined annual revenues would exceed $50 mil. Invitrogen revenues were $31.4 mil. in 1998; net income was $3 mil. Novex generated revenues of $23.1 mil. for the fiscal year ended March 31, and net income of $1.1 mil. Acquisition of Novex is part of Invitrogen's strategy "to expand our leadership in providing products that accelerate gene discovery and analysis," the firm says